Advances in novel drug delivery strategies for breast cancer therapy

Artificial Cells, Blood Substitutes, and Biotechnology

Volumn 38, Issue 5, 2010, Pages 230-249

  Dhankhar, Ritu ^a   Vyas, Suresh P ^b   Jain, Arvind K ^a   Arora, Sahil ^a   Rath, Goutam ^a   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b DR H S GOUR UNIVERSITY   (India)

Author keywords

breast cancer; drug targeting; growth factor receptor; liposomes; nanoparticles

Indexed keywords

ANTICANCER DRUG; ANTITUMOR DRUGS; BREAST CANCER; CANCER DIAGNOSIS; DIAGNOSTIC DEVICE; DRUG TARGETING; GROWTH FACTOR; NANOCARRIERS; POLYMERIC MICELLE; QUANTUM DOT; TARGETED DRUG DELIVERY; THERAPEUTIC EFFECTS; THERAPEUTIC EFFICACY; TUMOR BIOLOGY;

DENDRIMERS; DIAGNOSIS; DRUG DELIVERY; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY; PEPTIDES; PHOSPHOLIPIDS; TUMORS;

FUNCTIONAL POLYMERS;

ANASTROZOLE; CARBON NANOTUBE; CYCLOPHOSPHAMIDE; DENDRIMER; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVACET; EXEMESTANE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GOSERELIN; LAPATINIB; LE DT; LEP ETU; LETROZOLE; LIPID EMULSION; LIPO DOX; LIPO TAXEN; LIPOSOME; MAGNETIC NANOPARTICLE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NANO VNB; NANOCARRIER; NANOCRYSTAL; NAVELBINE; PACLITAXEL; QUERCETIN; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TAMOXIFEN; THERMO DOX; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

AGE; ANOREXIA; ARTHRALGIA; BLEEDING; BREAST CANCER; BREAST FEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG TARGETING; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FATIGUE; FRACTURE; GENE SILENCING; HAIR LOSS; HORMONE SUBSTITUTION; HUMAN; INFECTION; LIFESTYLE; MENSTRUAL CYCLE; MICELLE; MOUTH PAIN; MUTATION; NANOTECHNOLOGY; NAUSEA; NONHUMAN; OBESITY; PARTIAL MASTECTOMY; POSTMENOPAUSE; POSTOPERATIVE CARE; PROTEIN TARGETING; PRURITUS; RADIATION EXPOSURE; REPRODUCTIVE HISTORY; REVIEW; SIDE EFFECT; SKIN ABRASION; SKIN REDNESS; THROMBOEMBOLISM; TUMOR VOLUME; UTERUS CANCER; VOMITING;

ANIMALS; APTAMERS, NUCLEOTIDE; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; GENE SILENCING; HUMANS; NANOSTRUCTURES; RNA, SMALL INTERFERING;

EID: 77956590417     PISSN: 10731199     EISSN: 15324184     Source Type: Journal    
DOI: 10.3109/10731199.2010.494578     Document Type: Review

References (114)

1. www.cancer.org
2. Tanaka, T., Decuzzi, P., Cristofanilli, M., Sakamoto, J. H., Tasciotti, E., Robertson, F. M., Ferrari, M. (2009). Nanotechnology for breast cancer therapy. Biomed Microdevices 11: 49-63.
3. Widakowich, C., Azambuja, E. de, Gil, T., Cardoso, F., Dinh, P., Awada, A., Piccart-Gebhart, M. (2007). Molecular targeted therapies in breast cancer: Where are we now? The International Journal of Biochemistry & Cell Biology 39: 1375-87.
4. www.about.com
5. www.medicinenet.com
6. Sharaf, L. H. (2006). Current trends and recent advances in breast cancer drug therapy. Cancer Therapy 4: 183-92.
7. Sengupta, S., Sasisekharan, R. (2007). Exploiting nano-technology to target cancer. Br. J. Cancer 96: 1315-19.
8. Nahar, M., Dutta, T., Murugesan, S., Asthana, A., Mishra, D., Rajkumar, V. , Tare, M., Saraf, S., Jain, N.K. (2006). Functional polymeric nanoparticles: an effi cient and promising tool for active delivery of bioactives. Critical Reviews in Therapeutic Drug Carrier Systems 23(4): 259-18.
9. Silva, G. A. (2007). Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. Surgical Neurology 67: 113-16.
10. Park, K. (2007). Nanotechnology: What it can do for drug delivery. J. Control. Release 120(1-2): 1-3.
11. Fang, J. Y. (2006). Nano- or submicron-sized liposomes as carriers for drug delivery. Chang Gung Med. J. 29: 358-62.
12. Tong, R., Cheng, J. (2007). Anticancer polymeric nanomedicines. Polymer Reviews 47: 345-381.
13. Torchilin, V. P. (2007). Nanocarriers. Pharmaceutical Research 24(12): 2333-34.
14. Vasir, J. K., Labhasetwar, V. (2005). Targeted drug delivery in cancer therapy. Technology in Cancer Research & Treatment 5(5): 363-74.
15. Vlerken, L. E. van, Vyas, T. K., Amiji, M. M. (2007). Poly (ethylene glycol)-modifi ed nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24(8): 1405-1414.
16. Nie, S., Xing, Y. , Kim, G. J., Simons, J. W. (2007). Nano-technology applications in cancer. Annu. Rev. Biomed. Eng. 9: 12.1-12.32.
17. Yezhelyev, M. V., Gao, X., Xing, Y. , Al-Hajj, A., Nie, S., O Regan, R. M. (2006). Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 7: 657-67.
18. Paolo, D. D., Pastorino, F., Brignole, C., Marimpietri, D., Loi, M., Ponzoni, M., Pagnan, G. (2008). Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment. Tumori 94: 246-53.
19. Park, J. W. (2002). Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4: 95-99.
20. Kullberg, M., Owens, J. L., Mann, K. (2010). Listeriolysin O enhances cytoplasmic delivery by Her-2 targeting liposomes. J. Drug Target. 18(4): 313-20.
21. Wong, M. Y., Chiu, G. N. (2010). Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast c ancer treatment. Anticancer Drugs. 21(4): 401-10.
22. Dai, W., Yang, T., Wang, X., Wang, J., Zhang, X., Zhang, Q. (2010). PHSCNK-modifi ed and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J Drug Target. 18(4): 254-63.
23. Drummond, D. C., Noble, C. O., Guo, Z., Hayes, M. E., Connolly-Ingram, C., Gabriel, B. S., Hann, B., Liu, B., Park, J. W., Hong, K., Benz, C. C., Marks, J. D., Kirpotin, D. B. (2010). Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 141(1): 13-21.
24. Tang, Q. Q., Shi, W., L ü , H. M., Peng, X. C., Wen, Y. J. (2009). Antitumor and antimetastatic activities of plasmid pcDNA3. 1-IP10 complexed with cationic liposome in mice with 4T1 breast cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 40(2): 195-98.
25. Gao, J., Zhong, W., He, J., Li, H., Zhang, H., Zhou, G., Li, B., Lu, Y., Zou, H., Kou, G., Zhang, D., Wang, H., Guo, Y., Zhong, Y. (2009). Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int. J. Pharm. 374(1-2): 145-52.
26. Heakal, Y. , Kester, M. (2009). Short-chain ceramide mimetics encapsulated nanoliposomal formulations has also demonstrated the inhibition of neurotensin (NTS) receptor 1-mediated MDA-MB-231 breast cancer progression. Mol. Cancer Res. 7(5): 724-34.
27. Rai, S., Paliwal, R., Gupta, P.N., Khatri, K., Goyal, A. K., Vaidya, B., Vyas, S. P. (2008). Solid Lipid Nanoparticles (SLNs) as a rising tool in drug delivery science: one step up in nanotechnology. Curr. Nanoscience, 4(1): 1-15.
28. Lu, B., Xiong, S.B., Yang, H., Yin, X.D., Chao, R.B. (2006). Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur. J. Pharm. Sci. 28(1-2): 86-95.
29. Wong, H. L., Rauth, A. M., Bendayan, R., Manias, J. L., Ramaswamy, M., Liu, Z., Erhan, S.Z., Wu, X. Y. (2006). A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res. 23(7): 1574-85.
30. Lee, M. K., Lim, S. J., Kim, C. K. (2007). Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 28(12): 2137-46.
31. Jain, S. K., Chaurasiya, A., Gupta, Y. , Jain, A., Dagur, P., Joshi, B., Katoch, V. M. (2008). Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J. Microencapsul. 25(5): 289-97.
32. Karasulu, H. Y. , Karabulut, B., Kantarci, G., Ozg ü ney, I., Sezgin, C., Sanli, U. A., G ö ker, E. (2004). Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line. Drug Deliv. 11(6): 345-50.
33. Jain, V., Nath, B., Gupta, G. K., Shah, P. P., Siddiqui, M. A., Pant, A. B., Mishra, P. R. (2009). Galactose-grafted chylomicron-mimicking emulsion: evaluation of specifi city against HepG-2 and MCF-7 cell lines. J. Pharm. Pharmacol. 61(3): 303-10.
34. Nornoo, A. O., Osborne, D. W., Chow, D. S. (2008). Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis. Int. J. Pharm. 349(1-2): 108-16.
35. Karasulu, H. Y., Karabulut, B., G ö ker, E., G ü neri, T., Gabor, F. (2007). Controlled release of methotrexate from w/o microemulsion and its in vitro antitumor activity. Drug Deliv. 14(4): 225-33.
36. Mendes, S., Graziani, S. R., Vit ó rio, T. S., Padoveze, A. F., Hegg, R., Bydlowski, S. P., Maranh ã o, R. C. (2009). Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy. Gynecol. Oncol. 112(2): 400-04.
37. Ueda, K., Asai, Y., Yoshimura, Y., Iwakawa, S. (2008). Effect of oil-in-water lipid emulsions prepared with fi sh oil or soybean oil on the growth of MCF-7 cells and HepG2 cells. J. Pharm. Pharmacol. 60(8): 1069-75.
38. Goldstein, D., Sader, O., Benita, S. (2007). Infl uence of oil droplet surface charge on the performance of antibody-emulsion conjugates. Biomed. Pharmacother. 61(1): 97-03.
39. Elnaggar, Y. S., El-Massik, M. A., Abdallah, O. Y. (2009). Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int. J. Pharm. 380(1-2): 133-41.
40. Kang, B. K., Chon, S. K., Kim, S. H., Jeong, S. Y., Kim, M. S., Cho, S. H., Lee, H. B., Khang, G. (2004). Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int. J. Pharm. 286(1-2): 147-56.
41. Morgan, M.T., Nakanishi, Y. , Kroll, D. J., Griset, A. P., Carnahan, M. A., Wathier, M., Oberlies, N. H., Manikumar, G., Wani, M. C., Grinstaff, M.W. (2006). Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res. 66: 11913-921.
42. Svenson, S., Tomalia, D. A. (2005). Dendrimers in biomedical applications-refl ections on the fi eld. Adv. Drug Del. Rev. 57: 2106-29.
43. Tomalia, D. A., Reyna, L. A., Svenson, S. (2007). Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans., 35(1): 61-67.
44. Goyal, A. K., Khatri, K., Vyas, S. P. (2008). Patents on non-viral mediated gene delivery. Recent Pat. DNA Gene Seq. 2: 44-60.
45. Santhakumaran, L. M., Thomas, T., Thomas, T. J. (2004). Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers. Nucleic Acids Res. 32(7): 2102-12.
46. Morgan, M. T., Nakanishi, Y. , Kroll, D. J., Griset, A. P., Carnahan, M. A., Wathier, M., Oberlies, N. H., Manikumar, G., Wani, M. C., Grinstaff, M. W. (2006). Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res. 66(24): 11913-21.
47. Pan, B., Cui, D., Sheng, Y. , Ozkan, C., Gao, F., He, R., Li, Q., Xu, P., Huang, T. (2007). Dendrimer-modifi ed magnetic nanoparticles enhance effi ciency of gene delivery system. Cancer Res. 67(17): 8156-63.
48. Kapp, T., Francke, P., Gust, R. (2008). Investigations on surface modifi ed dendrimers: enzymatic hydrolysis and uptake into MCF-7 breast cancer cells. Chem. Med. Chem. 3(4): 635-41.
49. Gu, S. Z., Zhao, X. H., Zhang, L. X., Li, L., Wang, Z. Y. , Meng, M., An, G. L. (2009). Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro. J. Zhejiang. Univ. Sci. B. 10(3): 159-67.
50. Wu, X. L., Kim, J. H., Koo, H., Bae, S. M., Shin, H., Kim, M. S., Lee, B. H., Park, R. W., Kim, I. S., Choi, K., Kwon, I. C., Kim, K., Lee, D. S. (2010). Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy. Bioconjug Chem. 21(2): 208-13.
51. Zheng, C., Qiu, L., Yao, X., Zhu, K. (2009). Novel micelles from graft polyphosphazenes as potential anti-cancer drug delivery systems: drug encapsulation and in vitro evaluation. Int. J. Pharm. 21 : 373(1-2): 133-40.
52. Yang, Y., Wang, J., Zhang, X., Lu, W., Zhang, Q. (2009). A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel. J. Control. Release. 135(2): 175-82.
53. Onyüksel, H., Jeon, E., Rubinstein, I. (2009). Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 274(2): 327-30.
54. Peng, C. L., Shieh, M. J., Tsai, M. H., Chang, C. C., Lai, P. S. (2008). Self-assembled star-shaped chlorin-core poly(epsilon-caprolactone)-poly(ethylene glycol) diblock copolymer micelles for dual chemo-photodynamic therapies. Biomaterials. 29(26): 3599-08.
55. Hu, Z., Luo, F., Pan, Y. , Hou, C., Ren, L., Chen, J., Wang, J., Zhang, Y. (2008). Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. J. Biomed. Mater. Res. A. 85(3): 797-07.
56. Zeng, F., Lee, H., Allen, C. (2006). Epidermal growth factor-conjugated poly(ethylene glycol)-block- poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjug Chem. 17(2): 399-09.
57. Mashal, A., Sitharaman, B., Li, X., Avti, P. , Sahakian, A., Booske, J., Hagness, S. (2010). Toward carbon-nanotube-based theranostic agents for microwave detection and treatment of breast cancer: enhanced dielectric and heating response of tissue-mimicking materials. IEEE Trans Biomed Eng. 99 (DOI: 10.1109/TBME.2010.2042597).
58. Samor ì , C., Ali-Boucetta, H., Sainz, R., Guo, C., Toma, F. M., Fabbro, C., daRos, T., Prato, M., Kostarelos, K., Bianco, A. (2010). Enhanced anticancer activity of multi-walled carbon nanotube-methotrexate conjugates using cleavable linkers. Chem Commun (Camb). 46(9): 1494-96.
59. Xiao, Y. , Gao, X., Taratula, O., Treado, S., Urbas, A., Holbrook, R. D., Cavicchi, R. E., Avedisian, C. T., Mitra, S., Savla, R., Wagner, P.D., Srivastava, S., He, H. (2009). Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells. BMC Cancer. 9: 351-62.
60. Bellucci, S., Chiaretti, M., Cucina, A., Carru, G. A., Chiaretti, A. I. (2009). Multiwalled carbon nanotube buckypaper: toxicology and biological effects in vitro and in vivo. Nanomedicine (Lond). 4(5): 531-40.
61. Weng, X., Wang, M., Ge, J., Yu , S., Liu, B., Zhong, J., Kong, J. (2009). Carbon nanotubes as a protein toxin transporter for selective HER2-positive breast cancer cell destruction. Mol Biosyst. 5(10): 1224-31.
62. Pan, B., Cui, D., Xu, P., Ozkan, C., Feng, G., Ozkan, M., Huang, T., Chu, B., Li, Q., He, R., Hu, G. (2009). Synthesis and characterization of polyamidoamine dendrimer-coated multi-walled carbon nanotubes and their application in gene delivery systems. Nanotechnology. 20(12): 125101.
63. Ou, Z., Wu, B., Xing, D., Zhou, F., Wang, H., Tang, Y. (2009). Functional single-walled carbon nanotubes based on an integrin alpha v beta 3 monoclonal antibody for highly effi cient cancer cell targeting. Nanotechnology. 20(10): 105102.
64. Dreaden, E. C., Mwakwari, S. C., Sodji, Q. H., Oyelere, A. K., El-Sayed, M. A. (2009). Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment. Bioconjug Chem. 20(12): 2247-53.
65. Chanda, N., Shukla, R., Katti, K. V. , Kannan, R. (2009). Gastrin releasing protein receptor specifi c gold nanorods: breast and prostate tumor avid nanovectors for molecular imaging. Nano Lett. 9(5): 1798-05.
66. Xu, C., Wang, B., Sun, S. (2009). Dumbbell-like Au-Fe3O4 nanoparticles for target-specifi c platin delivery. J. Am. Chem. Soc. 131(12): 4216-17.
67. Lee, S., Chon, H., Lee, M., Choo, J., Shin, S. Y. , Lee, Y. H., Rhyu, I. J., Son, S. W., Oh, C. H. (2009). Surface-enhanced Raman scattering imaging of HER2 cancer markers overexpressed in single MCF7 cells using antibody conjugated hollow gold nanospheres. Biosens Bioelectron. 24(7): 2260-63.
68. Li, J. L., Wang, L., Liu, X. Y. , Zhang, Z. P., Guo, H. C., Liu, W. M., Tang, S. H. (2009). In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett. 274(2): 319-26.
69. Baulida, J., Kraus, M. H., Alimandi, M., Fiore, P. P. D., Carpenter, G. (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271(9): 5251-57.
70. Brennan, P. J., Kumogai, T., Berezov, A., Murali R., Greene, M. I. (2000). HER2/Neu: mechanisms of dimerization/ oligomerization. Oncogene 19(53): 6093-01.
71. Frankel, A. E. (2002). New HER2-directed therapies for breast cancer. Clinical Cancer Research 8: 1699-01.
72. Nair, P. (2005). Epidermal growth factor receptor family and its role in cancer progression .Current Science 88(6): 890-98.
73. Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., Leahy, D. J. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-60.
74. Hudis, C. A. (2007). Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357: 39-51.
75. Seidman, A., Hudis, C., Pierri M. K. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20: 1215-21.
76. Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., Sliwkowski, M. X. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4): 317-28.
77. Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., Scher, H. I., Sliwkowski, M. X. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-37.
78. Rochefort, H., Glondu, M., Sahla, M. E., Platet, N., Garcia, M. (2003). How to target estrogen receptor-negative breast cancer? Endocrine-Related Cancer 10: 261-66.
79. Wu, H., Yupeng Chen, Y., Jing Liang, J., Bin Shi, B., Ge, Wu, Zhang, Y., Wang, D., Li, R., Xia, Yi, Hua, Zhang, Luyang, Sun and Yongfeng, Shang. (2005). Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulate dendometrial carcinogenesis. Nature 438: 981-987.
80. Shao, W., Brown, M. (2004). Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 6: 39-52.
81. Michaud, L. B. (2008). Treatment-experienced breast cancer. Am. J. Health Syst. Pharm. 65(10): S4-S9.
82. Sheikh, M. S., Garcia, M., Pujol, P., Fontana, J. A., Rochefort, H. (1994-1995). Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers? Invasion Metastasis 14(1-6): 329-336.
83. Ferrara, N., Henzel, W. J. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specifi c for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161(2): 851-858.
84. Shibuya, M., Claesson-Welsh, L. (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312(5): 549-560.
85. Toi, M., Bando, H., Ogawa, T., Muta, M., Hornig, C., Weich, H. A. (2002). Signifi cance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int. J. Cancer 98(1): 14-18.
86. Caine, G. J., Blann, A. D., Stonelake, P. S., Ryan, P., Lip, G. Y. (2003). Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur. J. Clin. Invest. 33(10): 883-890.
87. Moulik, S., Chatterjee, A. (2007). Vascular endothelial growth factor (VEGF) & tumour angiogenesis. Indian J. Med. Res. 125: 715-716.
88. Rosen, L. S. (2005). VEGF-targeted therapy: therapeutic potential and recent advances. The Oncologist 10(6): 382-391.
89. McCance, K. L., Jones, R. E. (2003). Estrogen and insulin crosstalk: breast cancer risk implications. The Nurse Practitioner 28(5): 12-23.
90. Gill, Z. P., Perks, C. M., Newcomb, P. V., Holly, J. M. P. (1997). Insulin-like Growth Factor-binding Protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. The Journal of Biological Chemistry 272(41): 25602-607.
91. Diorio, C., Brisson, J., Berube, S., Pollak, M. (2008). Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study. Breast Cancer Research 10(3): 1-8.
92. Missmer, S. A., Haiman, C. A., Hunter, D. J., Willett, W. C., Colditz, G. A., Speizer, F. E., Pollak, M. N., Hankinson, S. E. (2002). A sequence repeat in the insulin-like growth factor-1 and risk of breast cancer. Int. J. Cancer 100: 332-36.
93. Ren, Z., Cai, Q., Shu, X., Cai, H., Li, C., Yu , H., Gao, Y. , Zheng, W. (2004). Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiology Biomarkers & Prevention 13: 1290-95.
94. Ibrahim, Y. H., Yee, D. (2005). Insulin-like growth factor-I and breast cancer therapy. Clinical Cancer Research 11: 944s-50s.
95. Chang, E., Zhu, M., Drezek, R. (2007). Novel siRNA-based molecular beacons for dual imaging and therapy. Biotechnology Journal 2: 2-5.
96. Alper, J. (2006). Nanoparticles and siRNA-Partners on the Pathway to New Cancer Therapies, NCI Alliance for Nanotechnology in Cancer, 1-3.
97. Rossi, J. J. (2005). Protamine-antibody fragment fusions enable delivery of siRNAs to specifi c cells in mice. Nature Biotechnology 23(6): 682-84.
98. Song, E., Zhu, P., Lee, S. K., Chowdhury D., Kussman, S., Dykxhoorn, D. M., Feng, Y. , Palliser, D., Weiner, D. B., Shankar, P. , Marasco, W. A., Lieberman, J. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23(6): 709-17.
99. Chen, Y. , Stamatoyannopoulos, G., Song, C. (2003). Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Research 63: 4801-04.
100. Osta, W. A., Chen, Y. , Mikhitarian, K., Mitas, M., Salem, M., Hannun, Y. A., Cole, D. J., Gillanders, W. E. (2004). EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Research 64: 5818-24.
101. Vorhies, J. S., Nemunaitis, J. N. (2007). Nucleic acid aptamers for targeting of shRNAbased cancer therapeutics. Biologics: Targets & Therapy 1(4): 367-76.
102. Kim, S. H., Jeong, J. H., Chun, K. W., Park, T. G. (2005). Target-specifi c cellular uptake of PLGA nanoparticles coated with poly(L-lysine)- poly(ethylene glycol)-folate conjugate. Langmuir 21(19): 8852-57.
103. Ferreira, C. S. M., Cheung, M. C., Missailidis, S., Bisland, S., Gariepy, J. (2009). Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucl. Acids Res. 37(3): 866-76.
104. Gendler, S. J. (2001). MUC1, the renaissance molecule. J. Mammary Gland Biol. 6: 339-53.
105. Mi, Z., Guo, H., Russell, M. B., Liu, Y., Sullenger, B. A., Kuo, P. C. (2008). RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Molecular Therapy 7(1): 153-61.
106. Lin, N. U., Winer, E. P. (2004). New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors. Breast Cancer Res. 6: 204-10.
107. Wang, Q, Greene, M. I. (2008). Mechanisms of resistance to ErbB-targeted cancer therapeutics. J. Clin. Invest. 118(7): 2389-92.
108. Esteva, F. J. (2004). Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. The Oncologist 9(3): 4-9.
109. Zhang, Z. P. , Lee, S. H., Feng, S. S. (2007). Folate-decorated poly (lactide-coglycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 28: 1889-99.
110. Varki, A. (1994). Selectin ligands. Proc. Natl. Acad. Sci. USA 91: 7390-97.
111. Ghobrial, I. M., Witzig, T. E., Adjei, A. A. (2005). Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55: 178-94.
112. Ciardiello, F. (2002). An update of new targets for treatment: receptor mediated signals. Ann. Oncol. 13 (4): 29-38.
113. Banerjee, S., Zvelebil, M., Furet, P. , Mueller-Vieira, U., Evans, D. B., Dowsett, M., Martin L. A. (2009). The vascular endothelial growth factor receptor inhibitor PTK 787/ZK 222584 inhibits aromatase. Cancer Research 69(11): 4716-23.
114. Ogando, A. E., Ocana, A., Barrueco, R. R., Ferreira, L., Borges, J., Pandiella, A. (2008). Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2- overexpressing breast cancer cells. Ann. Oncol. 19(11): 1860-69.